Aclaris Therapeutics shares exploded higher during the regular session before facing mild pressure in after-hours trading. While the broader biotechnology sector remains active with ongoing FDA PDUFA calendar monitoring and clinical trial updates, there were no company-specific press releases or filings issued for Aclaris to account for the intraday volatility. Consequently, the stock appears to have moved in sympathy with general sector sentiment rather than as a result of a direct corporate catalyst.